TriangleTREATMENT READING
Peripheral T-Cell Non-Hodgkin Lymphoma
Choose a source section by treatment, subtype or setting. Patient and professional reading are labelled separately.
Selected text from the National Cancer Institute, with original links and dates. This Triangle reading page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
6 studies cited in this topic · see design and results →
Explore 2 related disease and treatment settings → · Source-derived catalogue; clinical review pending.
Late Effects of Treatment of Peripheral T-Cell Non-Hodgkin Lymphoma
Treatment of Anaplastic Large Cell Lymphoma
Treatment Options for Anaplastic Large Cell Lymphoma
Breast Implant–Associated Anaplastic Large Cell Lymphoma
Treatment of Nodal Lymphomas of T Follicular Helper Cell Origin
Treatment Options for Nodal Lymphomas of T Follicular Helper Cell Origin
Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified
Prognosis
Treatment Options for Peripheral T-Cell Lymphoma, Not Otherwise Specified
Treatment of Extranodal Natural Killer/T-Cell Lymphoma
Treatment Options for Extranodal Natural Killer/T-Cell Lymphoma
Treatment of Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas
Treatment Options for Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas
Treatment of Indolent T-Cell Lymphoma of the Gastrointestinal Tract
Treatment Options for Indolent T-Cell Lymphoma of the Gastrointestinal Tract
Treatment of Hepatosplenic T-Cell Lymphoma
Treatment Options for Hepatosplenic T-Cell Lymphoma
Treatment of Adult T-Cell Leukemia/Lymphoma
Treatment Options for Adult T-Cell Leukemia/Lymphoma
Biological and targeted therapies
Mogamulizumab
Brentuximab vedotin
Lenalidomide
Valemetostat
Zidovudine and interferon alfa
Cytotoxic chemotherapy and allogeneic SCT
Treatment of T-Cell Prolymphocytic Leukemia
Treatment Options for T-Cell Prolymphocytic Leukemia
Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Treatment Options for Relapsed or Refractory Peripheral T-Cell Lymphoma
Preserved source evidence · Independent clinical review pending · Not medical advice